Apogee Therapeutics, Inc.
Developing extended half-life antibodies for inflammatory and immunologic diseases, led by zumilokibart (APG777). AbbVie announced a definitive agreement to acquire Apogee on June 22, 2026; closing remains pending.
Immunology & inflammation · Extended half-life monoclonal antibodies · Late clinical (Phase 3 planned)